Emile Gogineni

Dr. Emile Gogineni

Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MMMatthew Mallory
Matthew Mallory
EGEmile Gogineni
Emile Gogineni
GJGuy C. Jones
Guy C. Jones
LGLester Greer
Lester Greer
CSCharles Simone
Charles Simone

22 February 2016 in Nature Communications
Verified
Journal Article
Open access
LMLiang Ma
Liang Ma
ZCZehua Chen
Zehua Chen
DHDa Wei Huang
Da Wei Huang
GKGeetha Kutty
Geetha Kutty
MIMayumi Ishihara
Mayumi Ishihara
JKJoseph A. Kovacs
Joseph A. Kovacs
Pneumocystis jiroveciiis a major cause of life-threatening pneumonia in immunosuppressed patients including transplant recipients and those with HIV/AIDS, yet surprisingly little is known about the biology of this fungal pathogen. Here we report near complete genome assemblies for threePneumocystisspecies that infect humans, rats and mice.Pneumocystisgenomes are highly compact relative to other fungi, with substantial reductions of ribosomal RNA genes, transporters, transcription factors and many metabolic pathways, but contain expansions of surface proteins, especially a unique and complex surface glycoprotein superfamily, as well as proteases and RNA processing proteins. Unexpectedly, the key fungal cell wall components chitin and outer chain N-mannans are absent, based on genome content and experimental validation. Our findings suggest thatPneumocystishas developed unique mechanisms of adaptation to life exclusively in mammalian hosts, including dependence on the lungs for gas and nutrients and highly efficient strategies to escape both host innate and acquired immune defenses.

19 March 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMonica Sassi
Monica Sassi
CRChiara Ripamonti
Chiara Ripamonti
NMNicolas J. Mueller
Nicolas J. Mueller
HYHirohisa Yazaki
Hirohisa Yazaki
GKGeetha Kutty
Geetha Kutty
JKJoseph A. Kovacs
Joseph A. Kovacs
Background. There have been numerous reports of clustered outbreaks of Pneumocystis pneumonia (PCP) at renal transplant centers over the past 2 decades. It has been unclear whether these outbreaks were linked epidemiologically to 1 or several unique strains, which could have implications for transmission patterns or strain virulence. Methods. Restriction fragment length polymorphism (RFLP) analysis was used to compare Pneumocystis isolates from 3 outbreaks of PCP in renal transplant patients in Germany, Switzerland, and Japan, as well as nontransplant isolates from both human immunodeficiency virus (HIV)–infected and uninfected patients. Results. Based on RFLP analysis, a single Pneumocystis strain caused pneumonia in transplant patients in Switzerland (7 patients) and Germany (14 patients). This strain was different from the strain that caused an outbreak in transplant patients in Japan, as well as strains causing sporadic cases of PCP in nontransplant patients with or without HIV infection. Conclusions. Two geographically distinct clusters of PCP in Europe were due to a single strain of Pneumocystis. This suggests either enhanced virulence of this strain in transplant patients or a common, but unidentified, source of transmission. Outbreaks of PCP can be better understood by enhanced knowledge of transmission patterns and strain variation.

15 November 2013 in Transplantation
Verified
Journal Article
Closed access
ARAndreas A. Rostved
Andreas A. Rostved
MSMonica Sassi
Monica Sassi
JKJørgen A.L. Kurtzhals
Jørgen A.L. Kurtzhals
SSSøren Schwartz Sørensen
Søren Schwartz Sørensen
ARAllan Rasmussen
Allan Rasmussen
JHJannik Helweg-Larsen
Jannik Helweg-Larsen
Background An outbreak of 29 cases of Pneumocystis jirovecii pneumonia (PCP) occurred among renal and liver transplant recipients (RTR and LTR) in the largest Danish transplantation centre between 2007 and 2010, when routine PCP prophylaxis was not used. Methods P. jirovecii isolates from 22 transplant cases, 2 colonized RTRs, and 19 Pneumocystis control samples were genotyped by restriction fragment length polymorphism and multilocus sequence typing analysis. Contact tracing was used to investigate transmission. Potential risk factors were compared between PCP cases and matched non-PCP transplant patients. Results Three unique Pneumocystis genotypes were shared among 19 of the RTRs, LTRs, and a colonized RTR in three distinct clusters, two of which overlapped temporally. In contrast, Pneumocystis control samples harbored a wide range of genotypes. Evidence of possible nosocomial transmission was observed. Among several potential risk factors, only cytomegalovirus viremia was consistently associated with PCP (P=0.03; P=0.009). Mycophenolate mofetil was associated with PCP risk only in the RTR population (P=0.04). Conclusion We identified three large groups infected with unique strains of Pneumocystis and provide evidence of an outbreak profile and nosocomial transmission. LTRs may be infected in PCP outbreaks simultaneously with RTRs and by the same strains, most likely by interhuman transmission. Patients are at risk several years after transplantation, but the risk is highest during the first 6 months after transplantation. Because patients at risk cannot be identified clinically and outbreaks cannot be predicted, 6 months of PCP chemoprophylaxis should be considered for all RTRs and LTRs.

15 January 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SPSimran Polce
Simran Polce
EGEmile Gogineni
Emile Gogineni
JAJeffrey Antone
Jeffrey Antone
MGMaged Mofied Ghaly
Maged Mofied Ghaly
DFDouglas Keith Frank
Douglas Keith Frank
BPBhupesh Parashar
Bhupesh Parashar

19 February 2011 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
PBPeter Burbelo
Peter Burbelo
KBKathleen E Bren
Kathleen E Bren
KCKathryn H. Ching
Kathryn H. Ching
EGEmile Gogineni
Emile Gogineni
SKShyam Kottilil
Shyam Kottilil
MIMichael J. Iadarola
Michael J. Iadarola
For many infectious agents, the detection of antibodies is critical for diagnosing, monitoring and understanding vaccine responses. To facilitate the highly quantitative and simultaneous analysis of antibodies against multiple proteins from infectious agents, we have developed Luciferase Immunoprecipitation Systems (LIPS) arrays. By configuring microtiter plates with multiple antigens and testing control and infected serum samples at one time in solution, LIPS arrays provided highly reproducible antibody titers to panels of antigens with a wide dynamic range of detection. While all serum samples showed similar positive and negative immunoreactivity with internal control antigens derived from Influenza and Renillaluciferase-alone protein, respectively, antibody titers to many HCV and HIV antigens were generally 10 to over 400-fold higher in the infected versus uninfected samples. Additional screening of 18 proteins from the EBV proteome with serum samples from healthy EBV-infected individuals showed statistically significant antibody titers to 50% of the proteins tested. Antibody titers for the different EBV antigens in the healthy EBV-infected individuals were markedly heterogeneous highlighting the complexity of host humoral responses. These results suggest that LIPS arrays offer a highly discriminating platform for simultaneously profiling a wide spectrum of antibodies associated with many infectious agents.